

## CLAIMS

We claim:

1. ~~A pharmaceutical agent for treating an amyloid disease in a patient, wherein the pharmacological agent comprises a therapeutically effective amount of plant matter from a plant of the genus *Uncaria*, species *tomentosa*, in combination with a therapeutically effective amount of one or more or the substances from the group of substances consisting of Ginkgo Biloba, Ginseng, Gotu Kola, Echinacea, Vitamin E, Selenium, Niacin or nicotinate, Folic acid, Vitamin B12, and Choline.~~
2. ~~The pharmacological agent of claim 1 wherein the therapeutically effective amount of *Uncaria tomentosa* comprises a dosage in the range of from about 10 to 1,000 mg/kg of body weight of the patient.~~
3. The pharmacological agent of claim 2 wherein the therapeutically effective amount of *Uncaria tomentosa* comprises a dosage in the range of from about 10 to 100 mg/kg of body weight of the patient.
4. ~~The pharmacological agent of claim 1 wherein said amyloid disease for treatment is selected from the group consisting of the amyloid associated with Alzheimer's disease, Down's syndrome and hereditary cerebral hemorrhage with amyloidosis of the Dutch type (wherein the specific amyloid is referred to as beta-amyloid protein or A $\beta$ ), the amyloid associated with chronic inflammation, various forms of malignancy and Familial Mediterranean Fever (wherein the specific amyloid is referred to as AA amyloid or inflammation-associated amyloidosis), the amyloid associated with multiple myeloma and other B-cell dyscrasias (wherein the specific amyloid is referred to as AL amyloid), the amyloid associated with type II diabetes (wherein the specific amyloid is referred to as amylin or islet amyloid), the amyloid associated with the prion diseases including Creutzfeldt-Jakob disease, Gerstmann-Straussler syndrome, kuru and animal scrapie (wherein the specific amyloid is referred to as PrP amyloid), the amyloid associated with long-term hemodialysis and carpal tunnel syndrome (wherein the specific amyloid is referred to as beta<sub>2</sub>-microglobulin amyloid), the amyloid associated with senile cardiac amyloid~~

and Familial Amyloidotic Polyneuropathy (wherein the specific amyloid is referred to as transthyretin or prealbumin), and the amyloid associated with endocrine tumors such as medullary carcinoma of the thyroid (wherein the specific amyloid is referred to as variants of procalcitonin).

5 5. The pharmacological agent of claim 4 wherein said amyloid disease for treatment is Alzheimer's Disease.

6. The pharmaceutical agent of claim 1 further comprising a pharmaceutically acceptable carrier, diluent or excipient.

7. The pharmaceutical agent of claim 1 wherein the therapeutically effective amount of plant matter has an amyloid inhibitory activity or efficacy greater than 50%.

8. A method of treating an amyloid disease in a patient, comprising the step of administering to the patient a therapeutically effective amount of plant matter from a plant of the genus *Uncaria*, species *tomentosa*, in combination with a therapeutically effective amount of one or more of the substances from the group of substances

15 consisting of Ginkgo Biloba, Ginseng, Gotu Kola, Echinacea, Vitamin E, Selenium, Niacin or nicotinate, Folic acid, Vitamin B12 or cobalamin, and Choline.

9. The method claim 8 wherein the therapeutically effective amount of *Uncaria tomentosa* is administered orally.

10. The method claim 8 wherein the therapeutically effective amount of *Uncaria tomentosa* is administered by aerosol spray.

11. The method claim 8 wherein the therapeutically effective amount of *Uncaria tomentosa* is administered in a parenterally injectable or infusible form.

12. A pharmaceutical agent for treating an amyloid disease in a patient, wherein the pharmacological agent comprises a therapeutically effective amount of plant matter from a plant of the genus *Uncaria*, species *tomentosa*, in combination with a therapeutically effective amount of one or more of the substances from the group of substances consisting of Bilberry, Dong Quai, Aloe Vera, Chromium Polynicotinate, Selenium, Vitamin B12 or cobalamin, Folic acid, Biotin, and Thiamine HCl, or vitamin B1.

13. ~~The pharmacological agent of claim 12 wherein the therapeutically effective amount of Uncaria tomentosa comprises a dosage in the range of from about 10 to 100 mg/kg of body weight of the patient.~~

14. The pharmacological agent of claim 12 wherein said amyloid disease for treatment is Diabetes.

15. ~~The pharmaceutical agent of claim 12 wherein the therapeutically effective amount of plant matter has an amyloid inhibitory activity or efficacy greater than 50%.~~

16. A method of treating an amyloid disease in a patient, comprising the step of administering to the patient a therapeutically effective amount of plant matter from a plant of the genus Uncaria, species tomentosa, in combination with a therapeutically effective amount of one or more <sup>selected</sup> ~~or the~~ substances from the group of substances consisting of Bilberry, Dong Quai, Aloe Vera, Chromium Polynicotinate, Selenium, Vitamin B12 or cobalamin, Folic acid, Biotin, and Thiamine HCl, or vitamin B1.